



Attorney Docket No. 25464X
IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GIL-AD et al.

Group Art Unit: 1615

Serial No.: 10/774,694

Examiner: Unknown

Filed: February 10, 2004

Title: **ANTI-PROLIFERATIVE DRUGS**

TRANSMITTAL LETTER

Commissioner of Patents
P.O. Box 1450
Alexandria, Va 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter;
- (2) Information Disclosure Statement;
- (3) PTO Form 1449 with 7 references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,

NATH & ASSOCIATES PLLC

By:


Gary M. Nath
Registration No. 26,965
Lee C. Heiman
Registration No. 41,827
Customer No. 20529

Date: July 19, 2004
NATH & ASSOCIATES PLLC
1030 15th Street NW - 6th Floor
Washington, D.C. 20005
GMN/LCH/ng:IDS_TR_LCH



Attorney Docket No. 25464X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GIL-AD et al.

Group Art Unit: 1615

Serial No.: 10/774,694

Examiner: Unknown

Filed: February 10, 2004

Title: **ANTI-PROLIFERATIVE DRUGS**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. § 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

[] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

[] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

The enclosed statement is accompanied by [check one]:
[] i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or
[] ii. a check in the amount required by 37 C.F.R. § 1.17(p).

[] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.
[] Certification report(e) below; and
[] a check in the amount as required by § 1.17(p).

[] d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
or

I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

Appropriate certification is attached.

f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or


Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:
or Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES

By:


Gary M. Nath
Registration No. 26,965
Lee C. Heiman
Registration No. 41,827
Customer No. 20529

Date: July 19, 2004

NATH & ASSOCIATES PLLC
1030 15th Street, N.W., 6th Floor
Washington, D.C. 20005
Tel. (202) 775-8383
Fax. (202) 775-8396 GMN/LCH/ng:IDSstatement_GMNLCH

JUL 19 2004

PATENT & TRADEMARK OFFICE

JULY 25

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Atty Docket
25464XSerial No.
10/774,694Applicant
GIL-AD et al.Filing Date
February 10, 2004Group Art Unit
1615

U. S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA	5,859,065	01.12.99	Brandes			08.01.97
	AB	US 2003/0082214 A1	05.01.03	Williams, et al.			08.17.01
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Trans-lation
	AL	WO 99/24415	20.05.99	JP			ABSTRACT
	AM	WO 01/87236	22.11.01	WO			N/A
	AN						
	AO						
	AP						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	Nordenberg, J. et al. "Effects of Psychotropic Drugs on Cell Proliferation and Differentiation", <u>Biochemical Pharmacology</u> , Elsevier Science Inc, vol.58 pp.1229-1236, 1999.
	AS	Silver, M.A. et al. "An Inhibitory Effect of Psychoactive Drugs on a Human Neuroblastoma Cell Line", <u>Biol. Psychiatry</u> , Society of Biological Psychiatry, vol.35 pp.824-826, 1994.
	AT	Strobl, J.S. "The cell death response to .gamma.-radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide", <u>Breast Cancer Research and Treatment</u> , vol.51(1) pp.83-95, 1998. (ABSTRACT)

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant.